Meyer Handelman Co. held its position in shares of Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 22,086 shares of the biopharmaceutical company’s stock at the end of the second quarter. Meyer Handelman Co.’s holdings in Shire PLC were worth $3,650,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. BlackRock Inc. boosted its position in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after buying an additional 1,400,275 shares in the last quarter. Glenview Capital Management LLC purchased a new position in Shire PLC during the first quarter valued at $176,927,000. Boston Partners boosted its position in Shire PLC by 80.7% in the first quarter. Boston Partners now owns 1,359,151 shares of the biopharmaceutical company’s stock valued at $236,805,000 after buying an additional 606,814 shares in the last quarter. Jana Partners LLC purchased a new position in Shire PLC during the first quarter valued at $94,903,000. Finally, New South Capital Management Inc. purchased a new position in Shire PLC during the first quarter valued at $87,954,000. 21.06% of the stock is owned by institutional investors.
Shares of Shire PLC (SHPG) traded up 2.38% on Friday, reaching $164.03. The company’s stock had a trading volume of 2,290,465 shares. Shire PLC has a 12 month low of $158.54 and a 12 month high of $209.22. The firm has a market cap of $48.86 billion, a P/E ratio of 168.24 and a beta of 1.60.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share for the quarter, beating the consensus estimate of $3.22 by $0.41. Shire PLC had a return on equity of 13.05% and a net margin of 2.14%. The firm had revenue of $3.57 billion for the quarter. During the same period in the previous year, the business earned $2.12 EPS. The business’s revenue was up 109.0% on a year-over-year basis. Equities analysts forecast that Shire PLC will post $14.81 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Meyer Handelman Co. Maintains Stake in Shire PLC (NASDAQ:SHPG)” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://stocknewstimes.com/2017/07/22/meyer-handelman-co-maintains-stake-in-shire-plc-nasdaqshpg.html.
Several research firms recently weighed in on SHPG. Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the company a “buy” rating in a research note on Saturday, July 1st. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Shire PLC in a research note on Wednesday, July 12th. Sanford C. Bernstein reissued a “market perform” rating and issued a $210.00 target price on shares of Shire PLC in a research note on Thursday, July 13th. BidaskClub cut shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Wednesday. Finally, BTIG Research reissued a “buy” rating and issued a $242.00 target price on shares of Shire PLC in a research note on Monday, July 17th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $227.45.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.
